Person: TURGUT, SEDA
Now showing 1 - 10 of 20
Publication Metadata onlyDoes DRD2 polymorphism influence the clinical characteristics of prolactinoma?(2015-10-01) Ilhan, MAHMUT MUZAFFER; Kahraman, Ozlem Timirci; Turan, Saime; Turgut, SEDA; Karaman, Ozcan; Zeybek, Umit; SHUKUROV, Samir; Yaylim, Ilhan; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULObjectives. - Genetic alterations explaining the clinical variability of prolactinomas still could not be clarified and dopamine D2 receptor (DRD2) polymorphism is a putative candidate for the variable response to dopaminergic treatment. The present study was conducted to investigate the influence of DRD2 TaqI A polymorphism on initial and follow-up characteristics of prolactinoma. Patients and methods. - Seventy-two patients with prolactinoma and 98 age and gender matched control subjects were recruited to the case-control study. Serum prolactin levels were assessed by enzyme-linked immunosorbent assay and DRD2 polymorphism was determined by polymerase chain reaction and restriction length polymorphism analysis. Results. - Decrease of prolactin levels and the tumor shrinkage after cabergoline treatment were 93.9 +/- 5.9% and 58.3 +/- 33.1% in microadenomas and 96.1 +/- 6.1% and 51.7 +/- 29.3 in macroadenomas (P = 0.02 and P > 0.05, respectively). We observed no significant difference for DRD2 genotypes and the alleles between the patients and healthy group (P > 0.05). Prolactin levels before treatment were correlated with tumor diameter before and after treatment and the percentage of prolactin decrease with treatment (P 0.05). Conclusion. - This study revealed that DRD2 TaqI A receptor polymorphism was not associated with the development of prolactinoma and its clinical characteristics. Future studies are needed to clarify the clinical implications of genetic alterations in prolactinoma. (C) 2015 Elsevier Masson SAS. All rights reserved. Publication Open AccessInvestigation of the Vitamin D Receptor Polymorphisms in Acromegaly Patients(2015-01-01) Ilhan, MAHMUT MUZAFFER; TOPTAS-HEKIMOGLU, Bahar; YAYLIM, Ilhan; Turgut, SEDA; TURAN, Saime; Karaman, Ozcan; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULObjective. The genetic structural alterations in the majority of somatotroph adenomas are not clarified and the search for novel candidate genes is still a challenge.We aimed to investigate possible associations between vitamin D receptor (VDR) polymorphisms and acromegaly. Design, Patients, and Methods. 52 acromegaly patients (mean age 45.7 ± 1.9 years) and 83 controls (mean age 43.1 ± 2.6 years) were recruited to the study. VDR polymorphism was determined by polymerase chain reaction-based restriction fragment length polymorphism methods. Results. The distribution of VDR genotypes showed a significant difference in the frequencies of VDR FokI genotypes between patients and controls (𝑃 = 0.034). VDR FokI ff genotype was significantly decreased in acromegaly patients (𝑃 = 0.035) and carriers of FokI Ff genotype had a 1.5-fold increased risk for acromegaly (OR: 1.5, 95% CI: 1.07–2.1; 𝑃 = 0.020). IGF1 levels after treatment were significantly higher in patients carrying the Ff genotype compared to carrying ff genotype (𝑃 = 0.0049). 25(OH)D3 levels were significantly lower in acromegaly patients (𝑃 < 0.001). Conclusions. Our study suggests that VDR FokI genotypes might affect the development of acromegaly and VDR polymorphisms may play a role in the course of acromegaly as a consequence of altering hormonal status. Publication Metadata onlyA novel AVP gene mutation in a Turkish family with neurohypophyseal diabetes insipidus(2016-03-01) Ilhan, MAHMUT MUZAFFER; Tiryakioglu, N. O.; KARAMAN, O.; Coskunpinar, E.; YILDIZ, R. S.; TURGUT, SEDA; Tiryakioglu, D.; TOPRAK, HÜSEYİN; TASAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TURGUT, SEDA; TOPRAK, HÜSEYİN; TAŞAN, ERTUĞRULPurpose Familial neurohypophyseal diabetes insipidus (FNDI) is a rare, autosomal dominant, inherited disorder which is characterized by severe polydipsia and polyuria generally presenting in early childhood. In the present study, we aimed to analyze the AVP gene in a Turkish family with FNDI. Publication Open AccessDOES GRAVES- DISEASE AFFECT ESOPHAGEAL MOTILITY?(2018-07-01) Senturk, H; Karaman, Ö; İlhan, M; Turgut, SEDA; Arabaci, E; Taşan, E; TURGUT, SEDA; ŞENTÜRK, HAKANContext: The gastrointestinal tract is one of the most affected systems in hyperthyroidism. Although thyrotoxicosis is thought to be associated with gastrointestinal dysmotility, there are limited studies focused on motility disorders in hyperthyroidism. Objectives: We aimed to investigate the manometric measurements to determine if esophageal motility is affected in Graves' disease. Materials and methods: Thirty patients with Graves' disease (18 female and 12 male) and 30, age and sex matched, healthy controls (22 female and 8 male) were recruited to the study between 2015 and 2016. Esophageal manometry was performed using MMS (Medical Measurement Systems bv. The Netherlands) Solar GI - Air Charged Intelligent Gastrointestinal Conventional Manometry. Results: The mean lower esophageal sphincter pressure (LESP) was 16.9 ± 5.3 mmHg in hyperthyroid patients and 20.1 ± 8.8 mmHg in the control group and there was no significant difference (p>0.05). It was observed that the duration of contraction was 3.9 ± 0.7 s in healthy subjects and, significantly shorter 3.2 ± 0.5 s in hyperthyroid patients (p<0.001). Duration of contraction was negatively correlated with TSH receptor Ab titer in patients (p=0.006, r= -0.48). Also, it was observed that the duration of relaxation was negatively correlated with fT4 levels in the patient group (p<0.05, r= -0.46). Conclusion: In this study, we observed that esophageal motility can be affected via shortened duration of contraction in Graves' disease. The gastrointestinal symptoms due to possible motility dysfunctions should be considered in the evaluation of hyperthyroid patients. Publication Metadata onlyEvaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis.(2014-10-01) Cetin, GÜVEN; OZKAN, T; TURGUT, SEDA; Ali, Cikrikcioglu; CEM, AR M; AYER, M; UNLU, A; KARATOPRAK, CUMALİ; SEKIN, Y; ÇETİN, GÜVEN; TURGUT, SEDA; ÇELİK, ŞENGÜL; KARATOPRAK, CUMALİ Publication Metadata onlyRapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey(2015-01-01T00:00:00Z) Tasan, ERTUĞRUL; HANIMOGLU, Hakan; Turgut, SEDA; Ilhan, MAHMUT MUZAFFER; EVRAN, Sevket; KAYNAR, Mehmet Yasar; TAŞAN, ERTUĞRUL; TURGUT, SEDA; İLHAN, MAHMUT MUZAFFERGiant prolactinoma is a rare subset of macroadenomas. Limited studies demonstrated which therapy could be successfully used in the first-line therapy of giant prolactinoma. We presented a case with a 54x40x40 mm pituitary adenoma and optic chiasmatic compression with left sphenoid sinus invasion. The tumor caused a loss of visual field of the right side. Cabergoline treatment was started with dose of 1.5 mg/week. Fifteen days later, the clinical visual acuity examination showed a significant improvement in the patient with visual field defect. After the five years follow-up magnetic resonance imagining showed reduction of the adenoma size (17x12 mm) was significant. Our findings suggest that, cabergoline can be used as a first-line therapy in giant prolactinomas because tumoral shrinkage without a surgical procedure and rapid improvement in visual field defect is achieved with this medical treatment. Publication Metadata onlyDO WE REALLY TREAT ESSENTIAL THROMBOCYTHEMIA? A CLINICAL TRIAL OF 148 PATIENTS WITH ET(2014-10-01) ÇETİN, GÜVEN; Ozkan, T.; TURGUT, SEDA; Cevirme, N.; Hamdard, J.; Ayer, M.; Ekinci, S.; DAE, SHUTE AILIA; Ismayilova, M.; Gultepe, I.; Cikrikcioglu, M.; ÇETİN, GÜVEN; TURGUT, SEDA; ÇEVİRME, NİDAL; DAE, SHUTE AıLıA; ISMAYILOVA, MADINA Publication Open AccessEffects of Weight Loss with Bariatric Surgery on Platelet Count and Volume(2018-07-01) Ilhan, Muzaffer; KARAMAN, ÖZCAN; Yasin, Ayse Irem; TURGUT, SEDA; TAŞAN, ERTUĞRUL; KARAMAN, ÖZCAN; YASİN, AYŞE İREM; TURGUT, SEDA; TAŞAN, ERTUĞRULObjective: Obesity is a chronic metabolic disorder that leads to the increased risk of cardiovascular diseases. This study aims to investigate the effect of weight loss on the platelet count and volume, which is associated with cardiovascular diseases. Methods: In total, 56 obese patients were recruited for the study. The parameters were retrospectively evaluated before and after 6 months of surgery. Results: The mean weight of the patients was 126.2±23.1 kg before surgery and 91.8±20.5 kg after surgery (p<0.001). The mean platelet counts were 292.5±58.6×10³/µL before surgery and 246.8±59.1×10³/µL after surgery (p<0.001). The mean platelet volumes were 10.4±1.0 fL and 11.6±0.9 fL before and after surgery, respectively (p<0.001). The mean platelet counts before surgery were correlated with the mean platelet volume, mean weight, and mean body mass index (p<0.01, r=−0.39, p<0.01, r=0.35, p<0.01, r=0.41, respectively). The mean platelet counts after surgery were correlated with the mean platelet volume (p<0.001, r=−0.68). Conclusion: This study demonstrated decreased platelet counts and increased platelet volume at 6 months after surgery in obese patients. Further long-term and prospective studies are warranted to clarify these results and pathopsychological mechanisms involved. Publication Metadata onlyParathyroid Carcinoma Case Report: Rapid Control of Refractory Hypercalcemia with Denosumab(2017-01-01) İLHAN, MAHMUT MUZAFFER; EKİNCİ, İSKENDER; KARAMAN, ÖZCAN; TURGUT, SEDA; TAŞAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TURGUT, SEDA; TAŞAN, ERTUĞRUL Publication Open AccessThe Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor Shrinkage(2017-05-01) Turgut, SEDA; Ilhan, Muzaffer; Turan, Saime; Karaman, Ozcan; Yaylim, Ilhan; Kucukhuseyin, Ozlem; Tasan, ERTUĞRUL; TURGUT, SEDA; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULAim: Prolactinomas are thought to arise from clonal expansion of a single mutated cell which is subjected to growth stimuli of several permissive factors, although the pathogenetic mechanisms underlying tumorigenesis remain unclear. The present study aimed to investigate the role of p16 (540C→G and 580C→T) and mouse double minute 2 (MDM2) (SNP309T→G) gene polymorphisms in tumorigenesis and characteristics of prolactinoma. Patients and methods: A total of 74 patients with prolactinoma and 100 age- and gender-matched healthy individuals were enrolled in the study. Serum prolactin levels were measured by enzyme-linked immunosorbent assay (ELISA). p16 and MDM2 polymorphisms were determined by polymerase chain reaction-restriction fragment polymorphism and agarose gel electrophoresis. Results: p16 540C→G genotype distribution was found to be: CC: 66.2%, CG: 28.4%, GG: 5.4%; p16 580C→T genotype distribution was found to be: CC: 82.4%, CT: 17.6%, TT: 0% and MDM2 genotype distribution was found to be: TT: 31.1%, TG: 47.3%, GG: 21.6% in patients with prolactinoma. Tumor diameter before treatment was correlated with prolactin levels before treatment and percentage of prolactin decrease with treatment (r=0.719, p<0.001, p=0.034 r=0.256, respectively). The number of patients with tumor size decrease of more than 50% in those with homozygous genotype (TT+GG) of MDM2 SNP309T→G was significantly higher than in heterozygous genotype (TG) carriers (odds ratio(OR)=0.18, 95% confidence interval(CI)=0.06-0.58; p=0.003). Conclusion: This study showed that p16 and MDM2 polymorphisms do not play a decisive role in tumorigenesis, but some genotypes of these polymorphisms might be associated with follow-up characteristics of prolactinoma.